Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Capital Expenditures (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Capital Expenditures data on record, last reported at $6.4 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 321.34% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $9.9 million, up 529.16%, while the annual FY2025 figure was $9.9 million, 529.16% up from the prior year.
  • Capital Expenditures reached $6.4 million in Q4 2025 per TARS's latest filing, up from $1.9 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.4 million in Q4 2025 and bottomed at -$1.4 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $675944.4, with a median of $330000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: surged 1636.36% in 2021, then crashed 408.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $586000.0 in 2021, then plummeted by 161.09% to -$358000.0 in 2022, then tumbled by 282.12% to -$1.4 million in 2023, then surged by 210.31% to $1.5 million in 2024, then surged by 321.34% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $6.4 million in Q4 2025, $1.9 million in Q3 2025, and $1.6 million in Q2 2025.